Tag - OTLK

Executive Moves

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Outlook Therapeutics (NASDAQ:OTLK) has appointed Lawrence Kenyon, EVP, CFO, and board member, as interim CEO, effective immediately. Russell Trenary has stepped down as the company’s president and CEO. Mr. Kenyon has...

December 4, 2024

Developments

Outlook Therapeutics receives CRL in wet AMD

Outlook Therapeutics (NASDAQ:OTLK) received a complete response letter (CRL) to the company’s biologics license application (BLA) for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development...

August 30, 2023

Markets

Cantor starts Outlook Therapeutics at OW; PT $4

Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...

February 6, 2023

Developments

Outlook Therapeutics reports topline results from Phase 2 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) reported topline results from its Phase 2 NORSE 1 trial evaluating ONS-5010 for the treatment of wet age-related macular degeneration (AMD). The study, whose primary endpoint is the...

August 26, 2020

Developments

Outlook Therapeutics completes enrollment in pivotal retinal disease trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its pivotal clinical trial evaluating LYTENAVA, an ophthalmic formulation of bevacizumab, for use in retinal indications. Formerly known as ONS-5010...

July 7, 2020

Developments

Outlook Therapeutics completes enrollment in Phase 3 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...

August 20, 2019

Tag - OTLK

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Outlook Therapeutics receives CRL in wet AMD

Cantor starts Outlook Therapeutics at OW; PT $4

Outlook Therapeutics reports topline results from Phase 2 wet AMD trial

Outlook Therapeutics completes enrollment in pivotal retinal disease trial

General

More